Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Neoplasm, Residual 2Primary Myelofibrosis 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Anemia, Aplastic 1

Interventions

blinatumomab 15Cyclophosphamide 15Cytarabine 14Azacitidine 11venetoclax 10fludarabine 10fludarabine phosphate 7Methotrexate 7Daunorubicin 7Rituximab 6Vincristine 5Mercaptopurine 5Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Dexamethasone 3Cladribine 3Busulfan 3Asparaginase 3thymoglobulin 2pembrolizumab 2pegaspargase 2nilotinib 2midostaurin 2daratumumab 2Vindesine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × daratumumab × Other hematologic neoplasm × Clear all
NCT07021677 2025-06-15

DARA_T_ALL

Tata Memorial Centre

Phase 2 Recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡